GlobeNewsWire
24 Aug 2026, 12:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA finalized guidance on July 14, 2026, providing a formal regulatory framework for the clinical investigation of psychedelic drugs, specifically including MDMA. — Regulatory clarity from the FDA significantly lowers the risk profile for companies developing psychedelic therapeutics, potentially accelerating clinical trials and approval paths.
+0.60SciSparc's subsidiary NeuroThera and Clearmind Medicine have published a U.S. patent application for a combination of MDMA and N-acylethanolamines (such as PEA) to treat PTSD, anxiety, and eating disorders. — Establishing intellectual property for a novel combination therapy creates a competitive moat and increases the intrinsic value of the collaboration for SPRC and CMND.
+0.40The NeuroThera-Clearmind collaboration has now generated a total of thirteen published patent applications globally. — The breadth of the joint IP portfolio suggests a sustained R&D pipeline, though it is less immediately impactful than the specific MDMA guidance and patent.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Which stocks this story touches
The company expanded its joint IP portfolio and received regulatory clarity from the FDA regarding MDMA development.
The company advanced its collaboration with Clearmind through a published patent application and favorable FDA guidance.
The company's subsidiary achieved a significant IP milestone with a new U.S. patent application for PTSD treatment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
6h ago
